Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcon stock logo
ALC
Alcon
$87.67
-1.8%
$89.25
$80.48
$101.10
$43.30B0.951.20 million shs1.67 million shs
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.95
-2.4%
$5.31
$3.96
$9.85
$2.61B0.412.62 million shs1.18 million shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.83
+0.5%
$11.98
$10.45
$21.69
$4.91B0.62715,138 shs618,722 shs
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.83
+0.5%
$11.98
$10.45
$21.69
$4.91B0.62715,138 shs618,722 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcon stock logo
ALC
Alcon
0.00%-0.30%+0.82%+4.77%-0.52%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
0.00%+7.99%+50.25%+30.25%-2.81%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+11.43%+19.79%+14.77%-5.66%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+11.43%+19.79%+14.77%-5.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcon stock logo
ALC
Alcon
1.8006 of 5 stars
2.43.00.80.01.10.81.3
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.1135 of 5 stars
0.93.00.04.02.53.30.6
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.1117 of 5 stars
3.12.00.00.01.81.72.5
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.1117 of 5 stars
3.12.00.00.01.81.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcon stock logo
ALC
Alcon
2.80
Moderate Buy$106.1321.05% Upside
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.86
Reduce$7.426.73% Upside
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.23
Hold$15.5412.38% Upside
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.23
Hold$15.5412.38% Upside

Current Analyst Ratings Breakdown

Latest BHC, BLCO, ALC, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
5/22/2025
Alcon stock logo
ALC
Alcon
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/20/2025
Alcon stock logo
ALC
Alcon
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/14/2025
Alcon stock logo
ALC
Alcon
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$102.00 ➝ $99.00
5/14/2025
Alcon stock logo
ALC
Alcon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/2/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
5/2/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcon stock logo
ALC
Alcon
$9.91B4.36$5.55 per share15.80$43.70 per share2.01
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.73B0.26$7.64 per share0.91($0.89) per share-7.81
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.02$1.87 per share7.41$18.57 per share0.74
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.02$1.87 per share7.41$18.57 per share0.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcon stock logo
ALC
Alcon
$1.02B$2.2538.9626.652.2411.28%6.95%4.92%8/19/2025 (Estimated)
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.49N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.411.56-7.50%2.62%1.28%7/30/2025 (Estimated)
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.411.56-7.50%2.62%1.28%7/30/2025 (Estimated)

Latest BHC, BLCO, ALC, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.9320N/AN/AN/A$2.47 billionN/A
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
5/13/2025Q1 2025
Alcon stock logo
ALC
Alcon
$0.77$0.73-$0.04$0.70$2.52 billion$2.33 billion
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcon stock logo
ALC
Alcon
N/AN/AN/AN/A4 Years
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A

Latest BHC, BLCO, ALC, and BLCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2025
Alcon stock logo
ALC
Alcon
annual$0.32700.3%5/14/20255/14/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcon stock logo
ALC
Alcon
0.21
2.70
1.66
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96

Institutional Ownership

CompanyInstitutional Ownership
Alcon stock logo
ALC
Alcon
53.86%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%

Insider Ownership

CompanyInsider Ownership
Alcon stock logo
ALC
Alcon
1.52%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.05%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alcon stock logo
ALC
Alcon
25,599493.24 million485.75 millionOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.29 millionOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.72 million351.03 millionOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.72 million351.03 millionOptionable

Recent News About These Companies

BLCO Stock Price Quote - Morningstar
Insider Stock Buying Reaches US$1.54m On Bausch + Lomb
BLCO - Bausch & Lomb Corp Executives - Morningstar
Bausch + Lomb Corporation (BLCO) - Yahoo Finance
Bausch + Lomb closes $790.6M offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alcon stock logo

Alcon NYSE:ALC

$87.67 -1.63 (-1.82%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$87.67 0.00 (0.00%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.95 -0.17 (-2.40%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$6.96 +0.01 (+0.09%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.83 +0.07 (+0.51%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$13.67 -0.16 (-1.16%)
As of 07/3/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.83 +0.07 (+0.51%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$13.67 -0.16 (-1.16%)
As of 07/3/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.